Alendronic Acid Produces Greater Effects than Risedronic Acid on Bone Density and Turnover in Postmenopausal Women with Osteoporosis: Results of FACTS1 1 Fosamax Actonel Comparison Trials. -International

Author： Reid David M.  

Publisher： Adis International

ISSN： 1173-2563

Source： Clinical Drug Investigation, Vol.26, Iss.2, 2006-01, pp. : 63-74

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Alendronic acid superior to risedronic acid in osteoporosis

By  

Inpharma, Vol. 1, Iss. 1459, 2004-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Alendronic acid superior to risedronic acid for osteoporosis

By  

Inpharma, Vol. 1, Iss. 1365, 2002-01 ,pp. : 11-12

Adis International

Access to resources Recommend Favorite

New horizons for zoledronic acid: results of the HORIZON trials in postmenopausal women with osteoporosis and after hip fracture

By Doggrell Sheila A  

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 4, 2008-03 ,pp. : 663-668

Informa Healthcare

Access to resources Recommend Favorite

Once-monthly risedronic acid is noninferior to daily risedronic acid in the treatment of postmenopausal osteoporosis

By  

Inpharma, Vol. 1, Iss. 1615, 2007-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Risedronic acid prevents bone loss in postmenopausal women with breast cancer, with or without aromatase inhibitor (AI) therapy,

By  

Inpharma, Vol. 1, Iss. 1637, 2008-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite